Clinical Trial Update: An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating enasidenib (AG-221) versus conventional care in older adults with late-stage IDH2-mutant acute myeloid leukemia has completed and resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Enasidenib (AG-221) (enasidenib)

Snippet

Sponsor: Celgene | Conditions: Leukemia, Myeloid, Isocitrate Dehydrogenase | Phase 3 | Status: COMPLETED | Results posted: 2022-09-10